<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777554</url>
  </required_header>
  <id_info>
    <org_study_id>CC-10004-CP-035</org_study_id>
    <nct_id>NCT02777554</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults</brief_title>
  <official_title>A Phase 1, Open Label, Randomized, Two Part Study to Evaluate the Pharmacokinetic Exposure of a Once-Daily (QD) Apremilast Formulation Relative to the Twice-Daily (BID) Reference Immediate Release (IR) Tablet and the Effect of Food on the QD Apremilast Formulation in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the relative bioavailability of apremilast&#xD;
      once-daily formulation relative to a twice daily formulation when administered as multiple&#xD;
      doses (Part 1), and when administered as a single dose under fasting and fed conditions (Part&#xD;
      2). Information on safety and tolerability will also be obtained.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: This is an open-label, randomized, two-period, two-sequence, crossover study in&#xD;
      healthy subjects. The study will consist of a screening phase, a baseline phase, two&#xD;
      treatment periods, and a follow-up phone call. Each period will be ten days in duration&#xD;
      including 7 days of dosing and sample collection for up to 72 hours post Day 7 morning dose.&#xD;
      There will be a washout between period 1 and period 2.&#xD;
&#xD;
      Part 2: This is an open-label, randomized, four-period, four-sequence crossover study to&#xD;
      evaluate the PK and exposure of apremilast following single dose administration of different&#xD;
      formulations of apremilast. Part 2 will consist of a screening phase, baseline, four&#xD;
      treatment periods, and a follow-up phone call. Each period will be four days in duration for&#xD;
      dosing (Day 1) and sample collection for up to 72 hours post Day 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 17, 2016</start_date>
  <completion_date type="Actual">November 22, 2016</completion_date>
  <primary_completion_date type="Actual">November 22, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Peak Maximum Plasma Concentration (Cmax) of Apremilast</measure>
    <time_frame>Apremilast IR: Day 7 predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, and 24 hours after the morning dose. Apremilast XL: Day 7 predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours after the morning dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours Postdose (AUC0-24) of Apremilast</measure>
    <time_frame>Apremilast IR: Day 7 predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, and 24 hours after the morning dose. Apremilast XL: Day 7 predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours after the morning dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Peak Maximum Plasma Concentration (Cmax) of Apremilast</measure>
    <time_frame>Apremilast IR: Predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, 24, 36, 48, 60, and 72 hours after the morning dose. Apremilast XL: Predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 30, 36, 48, 60, and 72 hours postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Observable Concentration (AUC0-t) of Apremilast</measure>
    <time_frame>Apremilast IR: Predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, 24, 36, 48, 60, and 72 hours after the morning dose. Apremilast XL: Predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 30, 36, 48, 60, and 72 hours postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-âˆž) of Apremilast</measure>
    <time_frame>Apremilast IR: Predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, 24, 36, 48, 60, and 72 hours after the morning dose. Apremilast XL: Predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 30, 36, 48, 60, and 72 hours postdose.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events</measure>
    <time_frame>Part 1: Up to 7 days after last dose in each treatment period (14 days); Part 2: Up to 7 days after each dose.</time_frame>
    <description>An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology.&#xD;
A serious AE is any AE occurring at any dose that:&#xD;
Resulted in death;&#xD;
Was life-threatening;&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization;&#xD;
Resulted in persistent or significant disability/incapacity;&#xD;
Was a congenital anomaly/birth defect;&#xD;
Constituted an important medical event. The Investigator determined the relationship between the administration of study drug and the occurrence of each AE as Not Suspected or Suspected as defined in the Protocol.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part 1: Apremilast 30 mg IR BID / Apremilast 75 mg XL QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received apremilast 30 mg immediate release (IR) tablet twice a day (BID) for 7 days in treatment period 1 then apremilast 75 mg extended release (XL) formulation once a day (QD) for 7 days in treatment period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Apremilast 75 mg XL QD / Apremilast 30 mg IR BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received apremilast 75 mg XL formulation once a day for 7 days in treatment period 1 then apremilast 30 mg IR tablet twice a day for 7 days in treatment period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose of apremilast in each of 4 treatment periods according to the following:&#xD;
Treatment period 1: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 2: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 3: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 4: Apremilast 75 mg XL formulation after a standard meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose of apremilast in each of 4 treatment periods according to the following:&#xD;
Treatment period 1: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 2: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 3: Apremilast 75 mg XL formulation after a standard meal; Treatment period 4: Apremilast 75 mg XL formulation after a high-fat meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose of apremilast in each of 4 treatment periods according to the following:&#xD;
Treatment period 1: Apremilast 75 mg XL formulation after a standard meal; Treatment period 2: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 3: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 4: Apremilast 30 mg IR tablet under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose of apremilast in each of 4 treatment periods according to the following:&#xD;
Treatment period 1: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 2: Apremilast 75 mg XL formulation after a standard meal; Treatment period 3: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 4: Apremilast 75 mg XL formulation under fasted conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast IR</intervention_name>
    <description>Apremilast immediate release tablet</description>
    <arm_group_label>Part 1: Apremilast 30 mg IR BID / Apremilast 75 mg XL QD</arm_group_label>
    <arm_group_label>Part 1: Apremilast 75 mg XL QD / Apremilast 30 mg IR BID</arm_group_label>
    <arm_group_label>Part 2: Sequence 1</arm_group_label>
    <arm_group_label>Part 2: Sequence 2</arm_group_label>
    <arm_group_label>Part 2: Sequence 3</arm_group_label>
    <arm_group_label>Part 2: Sequence 4</arm_group_label>
    <other_name>OtezlaÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast XL</intervention_name>
    <description>Apremilast extended release formulation tablet</description>
    <arm_group_label>Part 1: Apremilast 30 mg IR BID / Apremilast 75 mg XL QD</arm_group_label>
    <arm_group_label>Part 1: Apremilast 75 mg XL QD / Apremilast 30 mg IR BID</arm_group_label>
    <arm_group_label>Part 2: Sequence 1</arm_group_label>
    <arm_group_label>Part 2: Sequence 2</arm_group_label>
    <arm_group_label>Part 2: Sequence 3</arm_group_label>
    <arm_group_label>Part 2: Sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must satisfy the following criteria to be enrolled in the study (Part 1 and Part&#xD;
        2):&#xD;
&#xD;
          1. Must understand and voluntarily sign a written Informed consent form (ICF) prior to&#xD;
             any study-related procedures being performed.&#xD;
&#xD;
          2. Must be able to communicate with the investigator, understand and comply with the&#xD;
             requirements of the study, and agree to adhere to restrictions and examination&#xD;
             schedules.&#xD;
&#xD;
          3. Male and female subjects of any race between 18 to 55 years of age (inclusive), and in&#xD;
             good health as determined by the Investigator at the time of signing the informed&#xD;
             consent document.&#xD;
&#xD;
          4. Have a body mass index (BMI) between 18 and 33 kg/m^2 (inclusive).&#xD;
&#xD;
          5. No clinically significant laboratory test results as determined by the investigator.&#xD;
&#xD;
          6. At the screening visit, must be afebrile, with supine systolic blood pressure (BP): 90&#xD;
             to 140 mmHg, supine diastolic BP: 50 to 90 mmHg, and pulse rate: 40 to 110 bpm.&#xD;
             Eligibility criteria for vital signs performed during check-in and/or predose on Day 1&#xD;
             will be at the discretion of the Investigator.&#xD;
&#xD;
          7. Must have a normal or clinically acceptable 12-lead electrocardiogram (ECG). Subjects&#xD;
             must have a QT interval corrected using the Fridericia formula (QTcF) value â‰¤ 450&#xD;
             msec.&#xD;
&#xD;
          8. Female subjects&#xD;
&#xD;
               1. Must have a negative pregnancy test&#xD;
&#xD;
               2. If postmenopausal: must have follicular stimulating hormone (FSH) test result &gt;&#xD;
                  40 IU/L and a negative pregnancy test&#xD;
&#xD;
          9. Contraception Requirements:&#xD;
&#xD;
             Must comply with the following acceptable forms of contraception. All Female of child&#xD;
             bearing potential (FCBP)1 must use one of the approved contraceptive options as&#xD;
             described below while taking apremilast and for at least 28 days after administration&#xD;
             of the last dose of the apremilast. At the time of study entry, and at any time during&#xD;
             the study when a FCBP's contraceptive measures or ability to become pregnant changes,&#xD;
             the Investigator will educate the subject regarding contraception options and the&#xD;
             correct and consistent use of effective contraceptive methods in order to successfully&#xD;
             prevent pregnancy.&#xD;
&#xD;
             All FCBP must have a negative pregnancy test at Screening and Day -1 of each Treatment&#xD;
             Period. All FCBP subjects who engage in activity in which conception is possible must&#xD;
             use one of the approved contraceptive options described below:&#xD;
&#xD;
             Option 1: Any one of the following highly effective methods: hormonal contraception&#xD;
             (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device&#xD;
             (IUD); tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom&#xD;
             (latex condom or non-latex condom NOT made out of natural [animal] membrane [for&#xD;
             example, polyurethane]); Plus one additional barrier(c) contraceptive sponge with&#xD;
             spermicide.&#xD;
&#xD;
             Male subjects (including those who have had a vasectomy) who engage in activity in&#xD;
             which conception is possible must use barrier contraception (latex or non-latex&#xD;
             condoms NOT made out of natural [animal] membrane [for example, polyurethane]) while&#xD;
             on Investigational Product (IP) and for at least 28 days after the last dose of IP.&#xD;
&#xD;
         10. Must agree to refrain from donating sperm, blood or plasma (other than for this study)&#xD;
             while participating in this study and for at least 28 days after the last dose of&#xD;
             investigational product.&#xD;
&#xD;
         11. Subject is willing and able to adhere to the study visit schedule and other protocol&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The presence of any of the following will exclude a subject from enrollment:&#xD;
&#xD;
          1. History of any clinically significant and relevant neurological, psychiatric,&#xD;
             gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic,&#xD;
             endocrine, hematological, allergic disease, drug allergies, or other major disorders.&#xD;
&#xD;
          2. Any condition which places the subject at unacceptable risk if he were to participate&#xD;
             in the study, or confounds the ability to interpret data from the study.&#xD;
&#xD;
        1 A female of childbearing potential is a sexually mature female who 1) has not undergone a&#xD;
        hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical&#xD;
        removal of both ovaries) or 2) has not been postmenopausal for at least 24 consecutive&#xD;
        months (that is, has had menses at any time during the preceding 24 consecutive months).&#xD;
&#xD;
        3. Use of any prescribed systemic or topical medication within 30 days of the first dose&#xD;
        administration (exception, FCBP may use hormonal contraception).&#xD;
&#xD;
        4. Use of any non-prescribed systemic or topical medication (including vitamin/mineral&#xD;
        supplements, and herbal medicines) within 14 days of the first dose administration.&#xD;
&#xD;
        5. Any surgical or medical condition possibly affecting drug absorption, distribution,&#xD;
        metabolism and excretion, eg, bariatric procedure, colon resection, irritable bowel&#xD;
        syndrome, Crohn's disease, etc. Subjects with cholecystectomy and appendectomy may be&#xD;
        included.&#xD;
&#xD;
        6. Exposure to an investigational drug (new chemical entity) within 30 days prior to the&#xD;
        first dose administration or 5 half-lives of that investigational drug, if known (whichever&#xD;
        is longer).&#xD;
&#xD;
        7. Donated blood or plasma within 8 weeks before the first dose administration to a blood&#xD;
        bank or blood donation center.&#xD;
&#xD;
        8. History of drug abuse (as defined by the current version of the Diagnostic and&#xD;
        Statistical Manual [DSM]) within 2 years before dosing, or a positive drug screen&#xD;
        reflecting consumption of illicit drugs.&#xD;
&#xD;
        9. History of alcohol abuse (as defined by the current version of the DSM) within 2 years&#xD;
        before dosing, or a positive alcohol screen.&#xD;
&#xD;
        10. Known to have hepatitis, or known to be a carrier of the hepatitis B surface antigen&#xD;
        (HBsAg) or hepatitis C antibody (HCV Ab), or have a positive result to the test for human&#xD;
        immunodeficiency virus (HIV) antibodies at screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance-Daytona Beach</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Inc</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <results_first_submitted>July 2, 2021</results_first_submitted>
  <results_first_submitted_qc>July 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 22, 2021</results_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Subjects</keyword>
  <keyword>Apremilast</keyword>
  <keyword>Pharmacokinetic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 2 clinical sites in the United States. The study consisted of 2 parts. Part 1 was a multiple-dose two-period, two-sequence, crossover study. Part 2 was a four-period, four-sequence crossover study. Both parts enrolled healthy volunteers.</recruitment_details>
      <pre_assignment_details>In Part 1 participants were randomly assigned to 1 of 2 treatment sequences. In Part 2 participants were randomly assigned to 1 of 4 treatment sequences.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1: Apremilast 30 mg IR BID / Apremilast 75 mg XL QD</title>
          <description>Participants received apremilast 30 mg immediate release (IR) tablet twice a day (BID) for 7 days in treatment period 1 then apremilast 75 mg extended release (XL) formulation once a day (QD) for 7 days in treatment period 2. There was a 5.5 to 9.5-day washout period between each treatment period.</description>
        </group>
        <group group_id="P2">
          <title>Part 1: Apremilast 75 mg XL QD / Apremilast 30 mg IR BID</title>
          <description>Participants received apremilast 75 mg XL formulation once a day for 7 days in treatment period 1 then apremilast 30 mg IR tablet twice a day for 7 days in treatment period 2. There was a 6 to 10-day washout period between each treatment period.</description>
        </group>
        <group group_id="P3">
          <title>Part 2: Sequence 1</title>
          <description>Participants received a single dose of apremilast in each of 4 treatment periods according to the following:&#xD;
Treatment period 1: Apremilast 30 mg IR tablet in the morning and evening under fasted conditions; Treatment period 2: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 3: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 4: Apremilast 75 mg XL formulation after a standard meal. There was a washout period of approximately 6 to 10 days between each treatment period.</description>
        </group>
        <group group_id="P4">
          <title>Part 2: Sequence 2</title>
          <description>Participants received a single dose of apremilast in each of 4 treatment periods according to the following:&#xD;
Treatment period 1: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 2: Apremilast 30 mg IR tablet in the morning and evening under fasted conditions; Treatment period 3: Apremilast 75 mg XL formulation after a standard meal; Treatment period 4: Apremilast 75 mg XL formulation after a high-fat meal. There was a washout period of approximately 6 to 10 days between each treatment period.</description>
        </group>
        <group group_id="P5">
          <title>Part 2: Sequence 3</title>
          <description>Participants received a single dose of apremilast in each of 4 treatment periods according to the following:&#xD;
Treatment period 1: Apremilast 75 mg XL formulation after a standard meal; Treatment period 2: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 3: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 4: Apremilast 30 mg IR tablet in the morning and evening under fasted conditions.&#xD;
There was a washout period of approximately 6 to 10 days between each treatment period.</description>
        </group>
        <group group_id="P6">
          <title>Part 2: Sequence 4</title>
          <description>Participants received a single dose of apremilast in each of 4 treatment periods according to the following:&#xD;
Treatment period 1: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 2: Apremilast 75 mg XL formulation after a standard meal; Treatment period 3: Apremilast 30 mg IR tablet in the morning and evening under fasted conditions; Treatment period 4: Apremilast 75 mg XL formulation under fasted conditions. There was a washout period of approximately 6 to 10 days between each treatment period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discharged early due to hurricane</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other - Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1</title>
          <description>Participants in Part 1 received apremilast 30 mg IR tablet BID for 7 days and apremilast 75 mg XL formulation QD for 7 days in each treatment period depending on sequence assignment.</description>
        </group>
        <group group_id="B2">
          <title>Part 2</title>
          <description>Participants in Part 2 received a single dose of the following treatments in 4 treatment periods according to sequence assignment:&#xD;
Apremilast 30 mg IR tablet in the morning and evening under fasted conditions;&#xD;
Apremilast 75 mg XL formulation after a high-fat meal;&#xD;
Apremilast 75 mg XL formulation under fasted conditions;&#xD;
Apremilast 75 mg XL formulation after a standard meal.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="124"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="144"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.8" lower_limit="19" upper_limit="55"/>
                    <measurement group_id="B2" value="34.7" lower_limit="20" upper_limit="53"/>
                    <measurement group_id="B3" value="37.4" lower_limit="19" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Peak Maximum Plasma Concentration (Cmax) of Apremilast</title>
        <time_frame>Apremilast IR: Day 7 predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, and 24 hours after the morning dose. Apremilast XL: Day 7 predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours after the morning dose.</time_frame>
        <population>The pharmacokinetic (PK) population (all participants who received at least one dose of apremilast and had at least one measurable concentration datum) with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Apremilast 30 mg IR BID</title>
            <description>Participants received apremilast 30 mg IR tablet BID for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Apremilast 75 mg XL QD</title>
            <description>Participants received apremilast 75 mg XL formulation QD for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Peak Maximum Plasma Concentration (Cmax) of Apremilast</title>
          <population>The pharmacokinetic (PK) population (all participants who received at least one dose of apremilast and had at least one measurable concentration datum) with available data.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="451" spread="49.0"/>
                    <measurement group_id="O2" value="459" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To assess the exposure between the extended release apremilast formulation, and Reference IR (30 mg reference IR BID) tablet following multiple oral doses, an analysis of variance (ANOVA) model, with sequence, period, and treatment as fixed effects, and subject nested within sequence as a random effect, was performed on the natural log-transformed Day 7 Cmax.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalent exposure of the QD formulation to the BID tablet was established if the 90% confidence intervals (CIs) of the geometric mean ratio for Day 7 AUC0-24 and Cmax were completely contained within the range of 80% to 125%.</non_inferiority_desc>
            <param_type>Ratio (%) of Geometric Means</param_type>
            <param_value>101.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.1</ci_lower_limit>
            <ci_upper_limit>108.5</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Apremilast 75 mg XL QD / Apremilast 30 mg IR BID) from an ANOVA model, expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours Postdose (AUC0-24) of Apremilast</title>
        <time_frame>Apremilast IR: Day 7 predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, and 24 hours after the morning dose. Apremilast XL: Day 7 predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, and 24 hours after the morning dose.</time_frame>
        <population>The PK population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Apremilast 30 mg IR BID</title>
            <description>Participants received apremilast 30 mg IR tablet BID for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Apremilast 75 mg XL QD</title>
            <description>Participants received apremilast 75 mg XL formulation QD for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours Postdose (AUC0-24) of Apremilast</title>
          <population>The PK population with available data</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6370" spread="51.2"/>
                    <measurement group_id="O2" value="6090" spread="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To assess the exposure between the extended release apremilast formulation, and Reference IR (30 mg reference IR BID) tablet following multiple oral doses, an ANOVA model, with sequence, period, and treatment as fixed effects, and subject nested within sequence as a random effect, was performed on the natural log-transformed Day 7 AUC0-24.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalent exposure of the QD formulation to the BID tablet was established if the 90% CIs of the geometric mean ratio for Day 7 AUC0-24 and Cmax were completely contained within the range of 80% to 125%.</non_inferiority_desc>
            <param_type>Ratio (%) of Geometric Means</param_type>
            <param_value>95.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.9</ci_lower_limit>
            <ci_upper_limit>102.2</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Apremilast 75 mg XL QD / Apremilast 30 mg IR BID) from an ANOVA model, expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Peak Maximum Plasma Concentration (Cmax) of Apremilast</title>
        <time_frame>Apremilast IR: Predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, 24, 36, 48, 60, and 72 hours after the morning dose. Apremilast XL: Predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 30, 36, 48, 60, and 72 hours postdose.</time_frame>
        <population>PK population; two participants were excluded from PK analyses due to predose concentrations &gt; 5% than their Cmax values.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Apremilast 30 mg IR BID (Fasted)</title>
            <description>Participants received one apremilast 30 mg IR tablet in the morning and one in the evening under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Apremilast 75 mg XL (Fasted)</title>
            <description>Participants received a single dose of apremilast 75 mg XL formulation under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Apremilast 75 mg XL (Standard Meal)</title>
            <description>Participants received a single dose of apremilast 75 mg XL formulation after a standard meal.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Apremilast 75 mg XL (High Fat Meal)</title>
            <description>Participants received a single dose of apremilast 75 mg XL formulation after a high-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Peak Maximum Plasma Concentration (Cmax) of Apremilast</title>
          <population>PK population; two participants were excluded from PK analyses due to predose concentrations &gt; 5% than their Cmax values.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379" spread="29.9"/>
                    <measurement group_id="O2" value="402" spread="32.5"/>
                    <measurement group_id="O3" value="436" spread="33.2"/>
                    <measurement group_id="O4" value="496" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To estimate the exposure of apremilast following single dose administration of extended release (QD) relative to the Reference IR (BID) tablet under fasted conditions, an ANOVA model with treatment, sequence, and period as fixed effects, and subject nested within sequence as a random effect, was performed on the natural log-transformed Cmax of apremilast.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio (%) of Geometric Means</param_type>
            <param_value>103.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.6</ci_lower_limit>
            <ci_upper_limit>115.4</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Apremilast 75 mg XL / Apremilast 30 mg IR BID) from an ANOVA model, expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To estimate the effect of food on the PK of a single oral dose of extended release apremilast (QD), an ANOVA model with treatment, sequence, and period as fixed effects, and subject nested within sequence as a random effect, was performed on the natural log-transformed Cmax of apremilast.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio (%) of Geometric Means</param_type>
            <param_value>90.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81.6</ci_lower_limit>
            <ci_upper_limit>101.3</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Apremilast 75 mg XL (Fasted) / Apremilast 75 mg XL (Standard Meal)) from an ANOVA model, expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>To estimate the effect of food on the PK of a single oral dose of extended release apremilast (QD), an ANOVA model with treatment, sequence, and period as fixed effects, and subject nested within sequence as a random effect, was performed on the natural log-transformed Cmax of apremilast.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio (%) of Geometric Means</param_type>
            <param_value>115.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>103.3</ci_lower_limit>
            <ci_upper_limit>128.1</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Apremilast 75 mg XL (High Fat) / Apremilast 75 mg XL (Standard Meal)) from an ANOVA model, expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>To estimate the effect of food on the PK of a single oral dose of extended release apremilast (QD), an ANOVA model with treatment, sequence, and period as fixed effects, and subject nested within sequence as a random effect, was performed on the natural log-transformed Cmax of apremilast.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio (%) of Geometric Means</param_type>
            <param_value>126.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>113.7</ci_lower_limit>
            <ci_upper_limit>140.8</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Apremilast 75 mg XL (High Fat) / Apremilast 75 mg XL (Fasted)) from an ANOVA model, expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Observable Concentration (AUC0-t) of Apremilast</title>
        <time_frame>Apremilast IR: Predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, 24, 36, 48, 60, and 72 hours after the morning dose. Apremilast XL: Predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 30, 36, 48, 60, and 72 hours postdose.</time_frame>
        <population>PK population; two participants were excluded from PK analyses due to predose concentrations &gt; 5% than their Cmax values.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Apremilast 30 mg IR BID (Fasted)</title>
            <description>Participants received one apremilast 30 mg IR tablet in the morning and one in the evening under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Apremilast 75 mg XL (Fasted)</title>
            <description>Participants received a single dose of apremilast 75 mg XL formulation under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Apremilast 75 mg XL (Standard Meal)</title>
            <description>Participants received a single dose of apremilast 75 mg XL formulation after a standard meal.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Apremilast 75 mg XL (High Fat Meal)</title>
            <description>Participants received a single dose of apremilast 75 mg XL formulation after a high-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Observable Concentration (AUC0-t) of Apremilast</title>
          <population>PK population; two participants were excluded from PK analyses due to predose concentrations &gt; 5% than their Cmax values.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7030" spread="31.5"/>
                    <measurement group_id="O2" value="6650" spread="42.5"/>
                    <measurement group_id="O3" value="7580" spread="31.1"/>
                    <measurement group_id="O4" value="7400" spread="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To estimate the exposure of apremilast following single dose administration of extended release (QD) relative to the Reference IR (BID) tablet under fasted conditions, an ANOVA model with treatment, sequence, and period as fixed effects, and subject nested within sequence as a random effect, was performed on the natural log-transformed AUC0-t of apremilast.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio (%) of Geometric Means</param_type>
            <param_value>92.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81.3</ci_lower_limit>
            <ci_upper_limit>106.2</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Apremilast 75 mg XL / Apremilast 30 mg IR BID) from an ANOVA model, expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To estimate the effect of food on the PK of a single oral dose of extended release apremilast (QD), an ANOVA model with treatment, sequence, and period as fixed effects, and subject nested within sequence as a random effect, was performed on the natural log-transformed AUC0-t of apremilast.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio (%) of Geometric Means</param_type>
            <param_value>86.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>74.9</ci_lower_limit>
            <ci_upper_limit>98.7</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Apremilast 75 mg XL (Fasted) / Apremilast 75 mg XL (Standard Meal)) from an ANOVA model, expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>To estimate the effect of food on the PK of a single oral dose of extended release apremilast (QD), an ANOVA model with treatment, sequence, and period as fixed effects, and subject nested within sequence as a random effect, was performed on the natural log-transformed AUC0-t of apremilast.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio (%) of Geometric Means</param_type>
            <param_value>97.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.9</ci_lower_limit>
            <ci_upper_limit>111.6</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Apremilast 75 mg XL (High Fat) / Apremilast 75 mg XL (Standard Meal)) from an ANOVA model, expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>To estimate the effect of food on the PK of a single oral dose of extended release apremilast (QD), an ANOVA model with treatment, sequence, and period as fixed effects, and subject nested within sequence as a random effect, was performed on the natural log-transformed AUC0-t of apremilast.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio (%) of Geometric Means</param_type>
            <param_value>113.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.8</ci_lower_limit>
            <ci_upper_limit>129.7</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Apremilast 75 mg XL (High Fat) / Apremilast 75 mg XL (Fasted)) from an ANOVA model, expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-âˆž) of Apremilast</title>
        <time_frame>Apremilast IR: Predose and at 0.5, 1, 2, 3, 5, 8, 12, 12.5, 13, 14, 15, 17, 20, 24, 36, 48, 60, and 72 hours after the morning dose. Apremilast XL: Predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 30, 36, 48, 60, and 72 hours postdose.</time_frame>
        <population>PK population; two participants were excluded from PK analyses due to predose concentrations &gt; 5% than their Cmax values.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Apremilast 30 mg IR BID (Fasted)</title>
            <description>Participants received one apremilast 30 mg IR tablet in the morning and one in the evening under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Apremilast 75 mg XL (Fasted)</title>
            <description>Participants received a single dose of apremilast 75 mg XL formulation under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Apremilast 75 mg XL (Standard Meal)</title>
            <description>Participants received a single dose of apremilast 75 mg XL formulation after a standard meal.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Apremilast 75 mg XL (High Fat Meal)</title>
            <description>Participants received a single dose of apremilast 75 mg XL formulation after a high-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-âˆž) of Apremilast</title>
          <population>PK population; two participants were excluded from PK analyses due to predose concentrations &gt; 5% than their Cmax values.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7100" spread="31.4"/>
                    <measurement group_id="O2" value="6680" spread="42.4"/>
                    <measurement group_id="O3" value="7600" spread="31.1"/>
                    <measurement group_id="O4" value="7450" spread="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To estimate the exposure of apremilast following single dose administration of extended release (QD) relative to the Reference IR (BID) tablet under fasted conditions, an ANOVA model with treatment, sequence, and period as fixed effects, and subject nested within sequence as a random effect, was performed on the natural log-transformed AUC0-âˆž of apremilast.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio (%) of Geometric Means</param_type>
            <param_value>92.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81.1</ci_lower_limit>
            <ci_upper_limit>105.9</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Apremilast 75 mg XL / Apremilast 30 mg IR BID) from an ANOVA model, expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To estimate the effect of food on the PK of a single oral dose of extended release apremilast (QD), an ANOVA model with treatment, sequence, and period as fixed effects, and subject nested within sequence as a random effect, was performed on the natural log-transformed AUC0-âˆž of apremilast.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio (%) of Geometric Means</param_type>
            <param_value>86.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>75.0</ci_lower_limit>
            <ci_upper_limit>98.8</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Apremilast 75 mg XL (Fasted) / Apremilast 75 mg XL (Standard Meal)) from an ANOVA model, expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>To estimate the effect of food on the PK of a single oral dose of extended release apremilast (QD), an ANOVA model with treatment, sequence, and period as fixed effects, and subject nested within sequence as a random effect, was performed on the natural log-transformed AUC0-âˆž of apremilast.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio (%) of Geometric Means</param_type>
            <param_value>97.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.0</ci_lower_limit>
            <ci_upper_limit>111.8</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Apremilast 75 mg XL (High Fat) / Apremilast 75 mg XL (Standard Meal)) from an ANOVA model, expressed as a percentage.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>To estimate the effect of food on the PK of a single oral dose of extended release apremilast (QD), an ANOVA model with treatment, sequence, and period as fixed effects, and subject nested within sequence as a random effect, was performed on the natural log-transformed AUC0-âˆž of apremilast.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio (%) of Geometric Means</param_type>
            <param_value>113.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.8</ci_lower_limit>
            <ci_upper_limit>129.7</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Apremilast 75 mg XL (High Fat) / Apremilast 75 mg XL (Fasted)) from an ANOVA model, expressed as a percentage.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events</title>
        <description>An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology.&#xD;
A serious AE is any AE occurring at any dose that:&#xD;
Resulted in death;&#xD;
Was life-threatening;&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization;&#xD;
Resulted in persistent or significant disability/incapacity;&#xD;
Was a congenital anomaly/birth defect;&#xD;
Constituted an important medical event. The Investigator determined the relationship between the administration of study drug and the occurrence of each AE as Not Suspected or Suspected as defined in the Protocol.</description>
        <time_frame>Part 1: Up to 7 days after last dose in each treatment period (14 days); Part 2: Up to 7 days after each dose.</time_frame>
        <population>All participants who received at least one dose of apremilast</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Apremilast 30 mg IR BID</title>
            <description>Participants received apremilast 30 mg IR tablet BID for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Apremilast 75 mg XL QD</title>
            <description>Participants received apremilast 75 mg XL formulation QD for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Apremilast 30 mg IR BID (Fasted)</title>
            <description>Participants received one apremilast 30 mg IR tablet in the morning and one in the evening under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Apremilast 75 mg XL (Fasted)</title>
            <description>Participants received a single dose of apremilast 75 mg XL formulation under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Apremilast 75 mg XL (Standard Meal)</title>
            <description>Participants received a single dose of apremilast 75 mg XL formulation after a standard meal.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Apremilast 75 mg XL (High Fat Meal)</title>
            <description>Participants received a single dose of apremilast 75 mg XL formulation after a high-fat meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events</title>
          <description>An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology.&#xD;
A serious AE is any AE occurring at any dose that:&#xD;
Resulted in death;&#xD;
Was life-threatening;&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization;&#xD;
Resulted in persistent or significant disability/incapacity;&#xD;
Was a congenital anomaly/birth defect;&#xD;
Constituted an important medical event. The Investigator determined the relationship between the administration of study drug and the occurrence of each AE as Not Suspected or Suspected as defined in the Protocol.</description>
          <population>All participants who received at least one dose of apremilast</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any treatment-emergent adverse event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE related to study drug leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Part 1: Up to 7 days after last dose in each treatment period (14 days); Part 2: Up to 7 days after each dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part 1: Apremilast 30 mg IR BID</title>
          <description>Participants received apremilast 30 mg IR tablet BID for 7 days.</description>
        </group>
        <group group_id="E2">
          <title>Part 1: Apremilast 75 mg XL QD</title>
          <description>Participants received apremilast 75 mg XL formulation QD for 7 days.</description>
        </group>
        <group group_id="E3">
          <title>Part 1 Total</title>
          <description>Participants in Part 1 received apremilast 30 mg IR tablet BID for 7 days and apremilast 75 mg XL formulation QD for 7 days in each treatment period depending on sequence assignment.</description>
        </group>
        <group group_id="E4">
          <title>Part 2: Apremilast 30 mg IR (Fasted)</title>
          <description>Participants received one apremilast 30 mg IR tablet in the morning and one in the evening under fasted conditions</description>
        </group>
        <group group_id="E5">
          <title>Part 2: Apremilast 75 mg XL (Fasted)</title>
          <description>Participants received a single dose of apremilast 75 mg XL formulation under fasted conditions.</description>
        </group>
        <group group_id="E6">
          <title>Part 2: Apremilast 75 mg XL (Standard Meal)</title>
          <description>Participants received a single dose of apremilast 75 mg XL formulation after a standard meal.</description>
        </group>
        <group group_id="E7">
          <title>Part 2: Apremilast 75 mg XL (High Fat Meal)</title>
          <description>Participants received a single dose of apremilast 75 mg XL formulation after a high-fat meal.</description>
        </group>
        <group group_id="E8">
          <title>Part 2 Total</title>
          <description>Participants in Part 2 received a single dose of the following treatments in 4 treatment periods according to sequence assignment:&#xD;
Apremilast 30 mg IR tablet in the morning and evening under fasted conditions;&#xD;
Apremilast 75 mg XL formulation under fasted conditions;&#xD;
Apremilast 75 mg XL formulation after a standard meal;&#xD;
Apremilast 75 mg XL formulation after a high-fat meal.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

